That illness came to be referred to as AIDS soon.

And there’s effective treatment, but no cure still. As CBS News Senior Correspondent Harry Smith reported on The Early Show Tuesday, there have been rumors before there is an acknowledged disease. Gay guys were getting sick. Many were getting a rare kind of cancer. These were dying. And no one knew why. Researchers place the puzzle pieces together and found the virus. It was insidious. And unassailable. Doctors state to have functional cure for HIV The clusters shortly became even more widespread and, there was an Helps epidemic. Needle-sharing medication users joined the unwell, as did people with hemophilia, who got contaminated from blood transfusions.Dennehy, M.D., Adam Finn, M.D., Paul D. Griffiths, M.D., Suzanne Luck, M.B., Ch.B., Kathleen Gutierrez, M.D., Natasha Halasa, M.D., James Homans, M.D., M.P.H., Andi L. Shane, M.D., M.P.H., Michael Sharland, M.D., Kari Simonsen, M.D., John A. Vanchiere, M.D., Ph.D., Charles R. Woods, M.D., Diane L. Sabo, Ph.D., Inmaculada Aban, Ph.D., Huichien Kuo, M.S., Scott H. James, M.D., Mark N. Prichard, Ph.D., Jill Griffin, R.N., Dusty Giles, R.N., Edward P. Acosta, Pharm.D., and Richard J. Whitley, M.D. For the National Institute of Allergy and Infectious Diseases Collaborative Antiviral Research Group: Valganciclovir for Symptomatic Congenital Cytomegalovirus Disease Congenital cytomegalovirus infection is the leading nongenetic cause of sensorineural hearing loss1-4 and is the most frequent known viral cause of mental retardation5; the disease affects 0.6 to 0.7 percent of live births in industrialized countries.6-8 A total of 10 percent of congenitally infected neonates have symptomatic disease at birth, of whom 35 percent have sensorineural hearing loss, up to two thirds have neurologic deficits, and 4 percent die during the newborn period.7-11 Although congenital CMV an infection overall is rare, it makes up about 21 percent of kids with hearing loss in birth and 24 percent of those with hearing loss at 4 years of age.1,12 The National Institute of Allergy and Infectious Illnesses Collaborative Antiviral Research Group discovered that among neonates with symptomatic congenital CMV disease relating to the central nervous system , ganciclovir administered intravenously over an interval of 6 weeks was connected with improved audiologic outcomes at six months of life, but there was suggestion that this benefit could wane over the first 24 months of life.13 Treated infants got fewer developmental delays, according to Denver Developmental evaluations, than untreated infants.14 In a follow-up study, the CASG determined the dose of oral valganciclovir that outcomes in systemic contact with ganciclovir that is similar to that with intravenous ganciclovir.15 Therapy with intravenous ganciclovir or oral valganciclovir for 6 weeks is currently a recognized treatment option for patients with symptomatic congenital CMV disease involving the CNS.16 Methods Research Population and Design Neonates with symptomatic congenital CMV disease, with or without CNS involvement, were eligible for enrollment.